Latest metastatic melanoma Stories

2009-04-14 07:00:00

WOBURN, Mass., April 14 /PRNewswire/ -- BioVex Inc, a company developing next generation biologics for the treatment and prevention of cancer and infectious disease, announced today that its OPTiM (OncoVEX Pivotal Trial in Melanoma) Phase 3 study with OncoVEX (GM-CSF) in previously treated patients with Stage III and Stage IV melanoma had initiated.

2009-02-10 08:58:46

Scientists have long wondered how melanoma cells travel from primary tumors on the surface of the skin to the brain, liver and lungs, where they become more aggressive, resistant to therapy, and deadly.

2008-11-03 06:00:21

BRANFORD, Conn., Nov. 3 /PRNewswire-FirstCall/ -- CuraGen Corporation announced today preliminary data from an ongoing Phase II trial of CR011-vcMMAE, an antibody-drug conjugate that targets GPNMB, for the treatment of patients with unresectable Stage III or Stage IV melanoma. Dr.

2008-10-14 09:00:11

Synta Pharmaceuticals Corp., (NASDAQ: SNTA) a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it has achieved operational milestones triggering $25 million in payment from GlaxoSmithKline (GSK) under its collaboration agreement for the development and commercialization of elesclomol.

2008-10-06 12:00:42

Provectus Pharmaceuticals, Inc. (OTCBB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced that that the interim safety analysis on the first 20 subjects in its phase 2 clinical trial for the treatment of metastatic melanoma has been completed.

2008-09-15 12:00:35

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that two-year follow up survival data from its Phase 2b clinical trial in metastatic melanoma were presented at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm.

2008-08-22 09:01:11

Synta Pharmaceuticals Corp., (NASDAQ: SNTA) today announced the publication of new findings in the American Association for Cancer Research journal, Molecular Cancer Therapeutics that describe the novel mechanism of action of elesclomol: driving programmed cell death (apoptosis) in cancer cells through the selective induction of oxidative stress.

2008-01-07 12:00:48

A patient at The Angeles Clinic and Research Institute is the first to enter a global, pivotal Phase 3 clinical trial for treating advanced melanoma.

2005-11-17 17:26:18

Northwestern University researchers have demonstrated how the microenvironments of two human embryonic stem cell (hESC) lines (federally approved) induced metastatic melanoma cells to revert to a normal, skin cell-like type with the ability to form colonies similar to hESCs. The researchers also showed that these melanoma cells were less invasive following culture on the microenvironments of hESCs.

Word of the Day
  • A pivoted catch designed to fall into a notch on a ratchet wheel so as to allow movement in only one direction (e.g. on a windlass or in a clock mechanism), or alternatively to move the wheel in one direction.
The word 'pawl' probably comes from a Latin word meaning 'stake'.